Lexeo Therapeutics
Agent57 out of 100, Top 25%. Agent Readiness. Open the scores section.Agent Readiness: 57/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust84 out of 100, Top 25%. Data Trust. Open the scores section.Data Trust: 84/100. Top 25%. Measured by StartupHub.ai. Median 61.Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases.
About
Lexeo Therapeutics is a New York City-based, clinical-stage genetic medicine company focused on developing AAV-mediated treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease. The company leverages pioneering science and a stepwise development approach to advance its pipeline of therapeutic candidates, aiming to address significant unmet medical needs.
Similar companies
A biotechnology company developing genetic therapies for rare disorders.
Shares Gene Therapy, Cardiovascular Disease
Leveraging the adaptive immune system to diagnose and treat disease.
Shares Biotech, HealthTech
A global oncology company developing and commercializing innovative cancer treatments.
Shares Biotech, MedTech
Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.
Shares Biotech, MedTech
Biopharmaceutical company focused on developing and commercializing innovative treatments for rare neurological disorders.
Shares Biotech, MedTech
Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests for cancer detection, recurrence monitoring, and treatment selection.
Shares Biotech, MedTech
Key facts
- Website
- lexeotx.com
- Headquarters
- New York City, United States
- Founded
- 2020
- Employees
- 91
- Total funding
- $495M (Public Offering)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 16 Oct 2025 | Public Offering | $135M | |
| 27 May 2025 | Private Placement | $80M | Frazier Life Sciences, Janus Henderson Investors |
| 11 Mar 2024 | Private Placement | $95M | Adage Capital Management |
| 9 Sept 2021 | Series B | $100M | D1 Capital Partners |
| 6 Jan 2021 | Series A | $85M | Omega Funds |
Tech stack
Detected on lexeotx.com, last scanned 5 Nov 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Tag Manager
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- Email provider
- Microsoft 365
- Cookie consent
- Osano
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is Lexeo Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Lexeo Therapeutics is 84 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Lexeo Therapeutics raised?
Lexeo Therapeutics has raised a total of $495M in funding. The most recent round on record is Public Offering.
How many employees does Lexeo Therapeutics have?
Lexeo Therapeutics has approximately 91 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for Lexeo Therapeutics:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
